BR112022018929A2 - Inibidores da ciclofilina e seus usos - Google Patents

Inibidores da ciclofilina e seus usos

Info

Publication number
BR112022018929A2
BR112022018929A2 BR112022018929A BR112022018929A BR112022018929A2 BR 112022018929 A2 BR112022018929 A2 BR 112022018929A2 BR 112022018929 A BR112022018929 A BR 112022018929A BR 112022018929 A BR112022018929 A BR 112022018929A BR 112022018929 A2 BR112022018929 A2 BR 112022018929A2
Authority
BR
Brazil
Prior art keywords
cyclophilin inhibitors
inhibitors
cyclophilin
organ
cyclophiline
Prior art date
Application number
BR112022018929A
Other languages
English (en)
Portuguese (pt)
Inventor
Mak Ching-Pong
Ma Fashu
Peel Michael
Fliri Hans
Original Assignee
Farsight Medical Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farsight Medical Tech Shanghai Co Ltd filed Critical Farsight Medical Tech Shanghai Co Ltd
Publication of BR112022018929A2 publication Critical patent/BR112022018929A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Analytical Chemistry (AREA)
BR112022018929A 2020-03-26 2021-03-25 Inibidores da ciclofilina e seus usos BR112022018929A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020081295 2020-03-26
CN2021078391 2021-03-01
PCT/CN2021/083013 WO2021190601A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112022018929A2 true BR112022018929A2 (pt) 2022-12-06

Family

ID=77891510

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018929A BR112022018929A2 (pt) 2020-03-26 2021-03-25 Inibidores da ciclofilina e seus usos

Country Status (13)

Country Link
US (3) US12673976B2 (cg-RX-API-DMAC10.html)
EP (2) EP4126905B1 (cg-RX-API-DMAC10.html)
JP (2) JP7761578B2 (cg-RX-API-DMAC10.html)
KR (2) KR20220158760A (cg-RX-API-DMAC10.html)
CN (2) CN115335389A (cg-RX-API-DMAC10.html)
AU (1) AU2021240762A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018929A2 (cg-RX-API-DMAC10.html)
CA (2) CA3172535A1 (cg-RX-API-DMAC10.html)
ES (1) ES3074820T3 (cg-RX-API-DMAC10.html)
IL (1) IL296586B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022011697A (cg-RX-API-DMAC10.html)
TW (1) TWI917366B (cg-RX-API-DMAC10.html)
WO (2) WO2021190601A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
GB202207348D0 (en) * 2022-05-19 2022-07-06 Cypralis Ltd Macrocyclic compounds and uses thereof
TW202438040A (zh) * 2023-03-03 2024-10-01 大陸商睿諾醫療科技(上海)有限公司 劑誘導的肝臟病症或疾病的治療和預防
WO2024245384A1 (en) * 2023-06-02 2024-12-05 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof
WO2026119135A1 (en) * 2024-12-03 2026-06-11 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
DE69832984T2 (de) * 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
ATE254630T1 (de) 1998-06-12 2003-12-15 Chem Ag C Cyclosporine
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
DK1436322T3 (da) 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
JP2007532507A (ja) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト 脳虚血ならびに脳および脊髄傷害の処置のためのサイクロスポリンの使用
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
CN101068829B (zh) * 2004-10-01 2012-05-30 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
CA2652662C (en) * 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
MX2011001152A (es) 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
RU2492181C2 (ru) 2009-01-30 2013-09-10 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CA2785978A1 (en) * 2009-12-30 2011-07-07 Scynexis, Inc. Cyclosporine analogues
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
DE102011111991A1 (de) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
GB201217560D0 (en) 2012-10-02 2012-11-14 Mitopharm Ltd Novel cyclic depsipeptide compounds and their uses
US20140213508A1 (en) 2012-10-19 2014-07-31 Scynexis, Inc. Antiviral macrocycles
GB201222455D0 (en) 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
CN108025039B (zh) 2015-06-30 2022-07-29 西普拉里斯有限公司 新颖的大环化合物
CN106902347A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 亲环孢素抑制剂的用途
CN106902346A (zh) 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 药物组合物及其制药用途
AU2017267560B2 (en) * 2016-05-17 2022-03-24 S&T Global Inc. Novel cyclosporin derivatives and uses thereof
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
CN111449050A (zh) 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Also Published As

Publication number Publication date
US20240352074A1 (en) 2024-10-24
AU2021240762A1 (en) 2022-10-06
EP4126905C0 (en) 2026-05-13
TW202144379A (zh) 2021-12-01
KR20220158760A (ko) 2022-12-01
MX2022011697A (es) 2022-10-07
KR20220158761A (ko) 2022-12-01
CA3172601A1 (en) 2021-09-30
IL296586B1 (en) 2026-04-01
EP4126904A1 (en) 2023-02-08
US20230174583A1 (en) 2023-06-08
ES3074820T3 (es) 2026-07-23
US12522634B2 (en) 2026-01-13
CN115298199A (zh) 2022-11-04
JP7761578B2 (ja) 2025-10-28
EP4126905B1 (en) 2026-05-13
US12673976B2 (en) 2026-07-07
TWI917366B (zh) 2026-03-11
EP4126905A1 (en) 2023-02-08
WO2021190604A1 (en) 2021-09-30
US20230110497A1 (en) 2023-04-13
JP2023518776A (ja) 2023-05-08
EP4126905A4 (en) 2024-05-29
IL296586A (en) 2022-11-01
IL296586B2 (en) 2026-08-01
JP2023518777A (ja) 2023-05-08
CA3172535A1 (en) 2021-09-30
WO2021190601A1 (en) 2021-09-30
EP4126904A4 (en) 2024-05-29
JP7776435B2 (ja) 2025-11-26
CN115335389A (zh) 2022-11-11
US12060440B2 (en) 2024-08-13

Similar Documents

Publication Publication Date Title
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
CO2021005987A2 (es) Compuestos de anillo fusionado
UY40021A (es) Inhibidores lisina acetiltransferasa 6a (kat6a) y usos de los mismos
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
CL2022000998A1 (es) Inhibidores de las cinasas raf
BR112022004802A2 (pt) Moduladores de il-17a e usos dos mesmos
BR112023016590A2 (pt) Inibidores de tyk2 e seus usos
BR112022011917A2 (pt) Fluoroalquil-oxadiazois e seus usos
BR112023016614A2 (pt) Inibidores de tyk2 e usos dos mesmos
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
MX376584B (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
BR112021017620A2 (pt) Compostos macrocíclicos
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
CL2023002223A1 (es) Inhibidores de cdk2 y métodos de uso de los mismos
CU20190073A7 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
SV2010003491A (es) 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
BR112023016678A2 (pt) Inibidores de tyk2 e usos dos mesmos
MX2023010491A (es) Composicion farmaceutica para el tratamiento o la prevencion de la miastenia gravis.
BR112022011321A2 (pt) Compostos, polímeros, dispositivos e seus usos
ECSP22085221A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CL2022001887A1 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas